ASRT vs. CNTB, RLMD, QTTB, ORMP, SCYX, ETON, ANVS, CUE, MIST, and IOBT
Should you be buying Assertio stock or one of its competitors? The main competitors of Assertio include Connect Biopharma (CNTB), Relmada Therapeutics (RLMD), Q32 Bio (QTTB), Oramed Pharmaceuticals (ORMP), SCYNEXIS (SCYX), Eton Pharmaceuticals (ETON), Annovis Bio (ANVS), Cue Biopharma (CUE), Milestone Pharmaceuticals (MIST), and IO Biotech (IOBT). These companies are all part of the "pharmaceutical preparations" industry.
Assertio (NASDAQ:ASRT) and Connect Biopharma (NASDAQ:CNTB) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, community ranking, profitability, media sentiment and institutional ownership.
49.0% of Assertio shares are owned by institutional investors. Comparatively, 58.7% of Connect Biopharma shares are owned by institutional investors. 3.2% of Assertio shares are owned by company insiders. Comparatively, 22.6% of Connect Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
In the previous week, Connect Biopharma had 1 more articles in the media than Assertio. MarketBeat recorded 3 mentions for Connect Biopharma and 2 mentions for Assertio. Assertio's average media sentiment score of 1.88 beat Connect Biopharma's score of 0.94 indicating that Assertio is being referred to more favorably in the media.
Connect Biopharma has lower revenue, but higher earnings than Assertio.
Assertio currently has a consensus price target of $5.50, suggesting a potential upside of 450.39%. Connect Biopharma has a consensus price target of $6.50, suggesting a potential upside of 316.67%. Given Assertio's higher possible upside, analysts plainly believe Assertio is more favorable than Connect Biopharma.
Assertio has a beta of 1, meaning that its stock price has a similar volatility profile to the S&P 500.Comparatively, Connect Biopharma has a beta of -0.49, meaning that its stock price is 149% less volatile than the S&P 500.
Assertio received 88 more outperform votes than Connect Biopharma when rated by MarketBeat users. However, 69.57% of users gave Connect Biopharma an outperform vote while only 58.76% of users gave Assertio an outperform vote.
Connect Biopharma has a net margin of 0.00% compared to Assertio's net margin of -234.40%. Assertio's return on equity of 10.80% beat Connect Biopharma's return on equity.
Summary
Assertio and Connect Biopharma tied by winning 7 of the 14 factors compared between the two stocks.
Get Assertio News Delivered to You Automatically
Sign up to receive the latest news and ratings for ASRT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ASRT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Assertio Competitors List
Related Companies and Tools
